{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:31:40Z","timestamp":1742401900589,"version":"3.37.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Swedish Cancer Society"},{"DOI":"10.13039\/501100007231","name":"Cancer Society in Stockholm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"crossref"}]},{"name":"King Gustav V Jubilee Fund"},{"name":"Cancer and Allergy Foundation"},{"name":"Karolinska Institutet Foundations"},{"name":"IMTAC"},{"DOI":"10.13039\/501100002706","name":"AFA Insurance","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002706","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Stockholm County Council"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.exphem.2015.08.009","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T22:34:17Z","timestamp":1440887657000},"page":"38-49.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in\u00a0vitro comparative study"],"prefix":"10.1016","volume":"44","author":[{"given":"Sandra Eketorp","family":"Sylvan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Skribek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Norin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orsolya","family":"Muhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2015.08.009_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.08.009_bib2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib3","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.3109\/10428194.2013.827786","article-title":"Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: A population-based study from a well-defined geographic region","volume":"55","author":"Eketorp Sylvan","year":"2014","journal-title":"Leuk lymphoma"},{"key":"10.1016\/j.exphem.2015.08.009_bib4","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1080\/10428190701573257","article-title":"The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy","volume":"48","author":"Tam","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2015.08.009_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","article-title":"Molecular pathways: Targeting the microenvironment in chronic lymphocytic leukemia\u2014Focus on the B-cell receptor","volume":"20","author":"Ten Hacken","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2015.08.009_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: Lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2015.08.009_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies","volume":"24","author":"Burger","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.exphem.2015.08.009_bib8","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1080\/10428190701559132","article-title":"Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel","volume":"48","author":"Markasz","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2015.08.009_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e3181628b76","article-title":"Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes","volume":"31","author":"Markasz","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.exphem.2015.08.009_bib11","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.exphem.2010.09.001","article-title":"Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin","volume":"38","author":"Skribek","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2015.08.009_bib12","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.3109\/10428194.2013.867486","article-title":"Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia","volume":"55","author":"Huang","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2015.08.009_bib13","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.18632\/genesandcancer.56","article-title":"Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma","volume":"6","author":"Otvos","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.exphem.2015.08.009_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/1471-2407-14-709","article-title":"Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions","volume":"14","author":"Szulkin","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2015.08.009_bib16","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1093\/bioinformatics\/bth349","article-title":"Java Treeview\u2014Extensible visualization of microarray data","volume":"20","author":"Saldanha","year":"2004","journal-title":"Bioinformatics"},{"key":"10.1016\/j.exphem.2015.08.009_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2015.08.009_bib19","unstructured":"ECOG Performance Status. Available at: http:\/\/www.npcrc.org\/files\/news\/ECOG_performance_status.pdf. [Accessed on: April 25,2015]."},{"key":"10.1016\/j.exphem.2015.08.009_bib20","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/sj.leu.2402651","article-title":"In\u00a0vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia","volume":"16","author":"Schwanen","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.08.009_bib21","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1535-7163.MCT-06-0358","article-title":"Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells","volume":"6","author":"Markasz","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2015.08.009_bib22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.V122.21.1304.1304","article-title":"Selective Bcl-2 inhibition with ABT-199 is highly active against chronic lymphocytic leukemia (CLL) irrespective of TP53 mutation or dysfunction) (abstract","volume":"122","author":"Anderson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.08.009_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-013-0189-7","article-title":"PI3-Kinase inhibitors in chronic lymphocytic leukemia","volume":"9","author":"Chang","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.exphem.2015.08.009_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.exphem.2015.08.009_bib26","article-title":"Bcl-2 Inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)","volume":"122","author":"Seymour","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib27","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.leu.2403281","article-title":"Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma","volume":"18","author":"Ansell","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.08.009_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3422.3422","article-title":"Efficacy and safety of YM155 in relapsed\/refractory non-Hodgkin's lymphoma patients enrolled in a Phase I study","volume":"110","author":"Papadopoulos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib29","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/cncr.26510","article-title":"A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma","volume":"118","author":"Cheson","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2015.08.009_bib30","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.96","article-title":"Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein","volume":"28","author":"Purroy","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2015.08.009_bib31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2015.08.009_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1636.1636","article-title":"A novel cyclin dependent kinase inhibitor P1446A induces apoptosis of chronic lymphocytic leukemia B cells","volume":"122","author":"Godbersen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.971.971","article-title":"Dinaciclib (SCH727965) is a novel cyclin dependent kinase inhibitor that promotes selective apoptosis in CLL cells and abrogates the protective effects of microenvironment cytokines","volume":"116","author":"Johnson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib34","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.871.871","article-title":"Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"122","author":"Flynn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","volume":"155","author":"Scarfo","year":"2013","journal-title":"Immunol Lett"},{"key":"10.1016\/j.exphem.2015.08.009_bib37","first-page":"4570","article-title":"Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia","volume":"9","author":"Pahler","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2015.08.009_bib38","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1158\/1078-0432.CCR-07-4427","article-title":"Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay","volume":"14","author":"Bonfils","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2015.08.009_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","article-title":"Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia","volume":"147","author":"Blum","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2015.08.009_bib40","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib41","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2015.08.009_bib42","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib43","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2011.08882.x","article-title":"Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: In\u00a0vivo evidence of immune activation and antitumour response","volume":"155","author":"Chanan-Khan","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2015.08.009_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.716.716","article-title":"Alemtuzumab plus oral dexamethasone, followed by alemtuzumab maintenance or allogeneic transplantation in ultra high-risk CLL: Updated results from a Phase II study of the Gcllsg and fcgcll\/MW (abstract)","volume":"120","author":"Stilgenbauer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with\u00a0relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2015.08.009_bib47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2015.08.009_bib48","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.325.325","article-title":"Determination of recommended Phase 2 dose of ABT-199 (GDC-0199) combined with rituximab(R) in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"124","author":"Roberts","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.526.526","volume":"122","author":"Eichhorst","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib50","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Bottcher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2015.08.009_bib51","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.08.009_bib52","doi-asserted-by":"crossref","unstructured":"Seymour FJ, Davids MS, Pagel JM, Kahl BR, Wierda WG, Puvvada Sea. ABT-199 (GDC-0199) in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: High response rates among patients with high risk disease features including unmutated IGHV. In: 19th Congress of the European Hematology Association (EHA), Milan, Italy, 12\u201315 June 2014:Abstract S702.","DOI":"10.1200\/jco.2014.32.15_suppl.7015"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1500630X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X1500630X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:10:08Z","timestamp":1654924208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X1500630X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0301472X1500630X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2015.08.009","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in\u00a0vitro comparative study","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2015.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}